<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2022-3128</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3128</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СЕРДЕЧНО-СОСУДИСТЫЙ РИСК</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOVASCULAR RISK FACTORS</subject></subj-group></article-categories><title-group><article-title>Сравнительная оценка кардиоваскулярного риска у лиц европейской и корейской этнической принадлежности с использованием шкал SCORE и SCORE2</article-title><trans-title-group xml:lang="en"><trans-title>Comparative assessment of cardiovascular risk in European and Korean ethnic groups in the Russian population using the SCORE and SCORE2</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8388-5566</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богданов</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogdanov</surname><given-names>D. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Богданов Дмитрий Ю. — ассистент института терапии и инструментальной диагностики, ФГБОУ ВО “Тихоокеанский государственный медицинский университет”; врач-кардиолог, КГБУЗ “Владивостокская клиническая больница № 1”</p><p>Владивосток</p></bio><bio xml:lang="en"><p>Vladivostok</p></bio><email xlink:type="simple">mity03@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0117-0349</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Невзорова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nevzorova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, директор Института терапии и инструментальной диагностики</p><p>Владивосток</p></bio><bio xml:lang="en"><p>Vladivostok</p></bio><email xlink:type="simple">mity03@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7990-3602</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестопалов</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestopalov</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Главный врач</p><p>Владивосток</p><p> </p></bio><bio xml:lang="en"><p>Vladivostok</p></bio><email xlink:type="simple">mity03@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО “Тихоокеанский государственный медицинский университет”;&#13;
КГБУЗ “Владивостокская клиническая больница № 1”</institution></aff><aff xml:lang="en"><institution>Pacific State Medical University;&#13;
Vladivostok Clinical Hospital № 1</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Тихоокеанский государственный медицинский университет»</institution></aff><aff xml:lang="en"><institution>Pacific State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>КГБУЗ «Владивостокская клиническая больница №1»</institution></aff><aff xml:lang="en"><institution>Vladivostok Clinical Hospital № 1</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>22</day><month>02</month><year>2022</year></pub-date><volume>21</volume><issue>3</issue><fpage>3128</fpage><lpage>3128</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Богданов Д.Ю., Невзорова В.А., Шестопалов Е.Ю., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Богданов Д.Ю., Невзорова В.А., Шестопалов Е.Ю.</copyright-holder><copyright-holder xml:lang="en">Bogdanov D.Y., Nevzorova V.A., Shestopalov E.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3128">https://cardiovascular.elpub.ru/jour/article/view/3128</self-uri><abstract><sec><title>Цель</title><p>Цель. Проведение сравнительной оценки кардиоваскулярного риска (КВР) у  лиц 40-49 лет европейской и  корейской этнической принадлежности, объединенных единой территорией проживания, с  использованием шкал оценки SCORE (Systematic Coronary Risk Evaluation) и обновленной шкалы SCORE — SCORE2.</p></sec><sec><title>Материал и  методы</title><p>Материал и  методы. Обследованы 397 условно-здоровых лиц европейской этнической группы (ЕЭГ) и  50 корейской этнической группы (КЭГ), у которых проведена оценка КВР по системам SCORE и SCORE2.</p></sec><sec><title>Результаты</title><p>Результаты. По системе SCORE медиана КВР в  ЕЭГ составила 0 [0-0] vs 0 [0-1]% в КЭГ (p&lt;0,001), при этом с клинической точки зрения группы между собой не различались. Система SCORE2 продемонстрировала клинически более значимые результаты: медиана риска у лиц ЕЭГ составила 5 [3-8]%, что для данной возрастной категории соответствует высокому КВР, а у лиц КЭГ — 8 [4-11]%, что соответствует очень высокому КВР (р=0,011). Оценка КВР у условно-здоровых лиц является определяющей в принятии решения для организации профилактических мероприятий. Согласно системе SCORE, 97,5% условно-здоровых лиц ЕЭГ и  96% лиц КЭГ отнесены к категориям низкого и умеренного риска. Высокий и очень высокий риск при использовании данной системы определялся у 2,5 и 4% среди европейцев и корейцев, соответственно. Вместе с тем, с помощью системы SCORE2 всего 10,3% обследованных европейца были отнесены к категории низкого/умеренного риска, а среди этнических корейцев ‒ 8%. При этом категория высокого и  очень высокого риска была обозначена соответственно для 63,7 и 25,9% в ЕЭГ и 40 и 52% в КЭГ. Установлено, что согласно вновь предлагаемой системе SCORE2 более половины корейцев в возрасте 40-49 лет уже имеют очень высокий КВР, что клинически значимо отличает данную группу от европейской популяции.</p></sec><sec><title>Заключение</title><p>Заключение. Система SCORE2 имеет более дифференцированный подход в определении индивидуального КВР. Оценка в системе SCORE2 уровня холестерин, не входящего в состав липопротеинов высокой плотности, делает ее более персонифицированной для использования в различных этнических популяциях.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To carry out a comparative assessment of cardiovascular risk (CVR) in people aged 40-49 years of European and Korean ethnicity with a single residence area using the Systematic Coronary Risk Evaluation (SCORE) and SCORE2 scales.</p></sec><sec><title>Material and methods</title><p>Material and methods. We examined 397 and 50 apparently healthy individuals of the European (EEG) and Korean (KEG) ethnic groups, respectively, who were evaluated for CVR according to the SCORE and SCORE2 charts.</p></sec><sec><title>Results</title><p>Results. According to the SCORE system, the median CVR in the EEG was 0 [0-0] vs 0 [0-1]% in the KEG (p&lt;0,001), while from a clinical point of view, the groups did not differ from each other. The SCORE2 system demonstrated more significant clinical results as follows: the median risk in EEG individuals was 5 [3-8]%, which corresponds to a high CVR for this age group, and 8 [4-11]% in KEG individuals, which corresponds to a very high CVR (p=0,011). CVR assessment in apparently healthy individuals is decisive in considering the preventive measures. According to the SCORE system, 97,5% and 96% of apparently healthy EEG and KEG individuals, respectively, are classified as low and moderate risk. High and very high risk when using this system was determined in 2,5 and 4% among Europeans and Koreans, respectively. However, using the SCORE2 system, only 10,3% of Europeans were classified as low/ moderate risk, and among ethnic Koreans — 8%. At the same time, the category of high and very high risk was designated, respectively, for 63,7 and 25,9% in the EEG and 40 and 52% in the KEG, respectively. It has been established that according to the SCORE2 system, more than half of Koreans aged 40-49 already have a very high CVR, which significantly distinguishes this group from the European population.</p></sec><sec><title>Conclusion</title><p>Conclusion. The SCORE2 system has a more differentiated approach in determining individual CVR. The SCORE2 assessment of non-high density lipoprotein cholesterol levels makes it more personalized for use in different ethnic populations.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>кардиоваскулярный риск</kwd><kwd>SCORE</kwd><kwd>SCORE2</kwd><kwd>этническая принадлежность</kwd><kwd>уровень холестерина</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cardiovascular risk</kwd><kwd>SCORE</kwd><kwd>SCORE2</kwd><kwd>ethnicity</kwd><kwd>cholesterol level</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при поддержке гранта РФФИ 19-29-01077 и  является частью государственного задания Министерства здравоохранения РФ “Клиникофенотипические и  молекулярно-генетические особенности старения сосудов у людей различных этнических групп”</funding-statement><funding-statement xml:lang="en">The worThe work was supported by the Russian Foundation for Basic Research grant № 19-29-01077 and is part of the state assignment of the Russian Ministry of Health “Clinical-phenotypic and molecular-genetic features of vascular aging in people of different ethnic groups.” ch grant № 19-29-01077 and is part of the state assignment of the Russian Ministry of Health “Clinical-phenotypic and molecular-genetic features of vascular aging in people of different ethnic groups.”</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Andrea B., Alberto A, Vincenzo C, et al. Cardiovascular disease and COVID-19: les liaisons dangereuses. Eur J Prev Cardiol. 2020;(10):1017-25. doi:10.1177/2047487320924501.</mixed-citation><mixed-citation xml:lang="en">Andrea B., Alberto A, Vincenzo C, et al. Cardiovascular disease and COVID-19: les liaisons dangereuses. Eur J Prev Cardiol. 2020;(10):1017-25. doi:10.1177/2047487320924501.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.</mixed-citation><mixed-citation xml:lang="en">Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Белов Ю.С., Ткаченко А.В. Интеллектуальные системы в Прогнозировании сердечнососудистых заболеваний. Программные продукты, системы и алгоритмы. 2019;(2):12-6. doi:10.15827/2311-6749.19.2.3.</mixed-citation><mixed-citation xml:lang="en">Belov YuS, Tkachenko AV. Intellectual systems in predicting cardiovascular diseases. Software products, systems and algorithms. 2019;(2):12-6. (In Russ.) doi:10.15827/2311-6749.19.2.3.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Кухарчук В.В., Ежов М.В., Сергиенко И.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;11(1):38. doi:10.34687/2219-8202.JAD.2020.01.0002.</mixed-citation><mixed-citation xml:lang="en">Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. Journal of atherosclerosis and dyslipisemias. 2020;11(1):38. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227-37. doi:10.1093/eurheartj/ehab484.</mixed-citation><mixed-citation xml:lang="en">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227-37. doi:10.1093/eurheartj/ehab484.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;13:ehab309. doi:10.1093/eurheartj/ehab309.</mixed-citation><mixed-citation xml:lang="en">SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;13:ehab309. doi:10.1093/eurheartj/ehab309.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11. doi:10.15829/1728-8800-2014-6-4-11.</mixed-citation><mixed-citation xml:lang="en">Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of noninfectious diseases risk factors in Russian population in 2012-2013 years. The results of ESSE-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Богданов Д.Ю., Невзорова В. А., Шуматов В.Б. и др. Факторы риска сердечно-сосудистых заболеваний у лиц европейской и корейской этнических групп, проживающих на территории Приморского края. Кардиоваскулярная терапия и профилактика. 2020;19(1):40-7. doi:10.15829/1728-8800-2020-1-2284.</mixed-citation><mixed-citation xml:lang="en">Bogdanov DYu, Nevzorova VA, Shumatov VB, et al. Risk factors for cardiovascular disease in ethnic Europeans and Koreans living in the Primorsky Krai. Cardiovascular Therapy and Prevention. 2020;19(1):40-7. (In Russ.) doi:10.15829/1728-8800-2020-1-2284.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С. А., Вилков В. Г., Метельская В. А. и др. Тридцатилетняя динамика средних характеристик липидов крови в популяциях Российской Федерации и США. Рациональная фармакотерапия в кардиологии. 2018;14(1):4-11. doi:10.20996/1819-6446-2018-14-1-4-11.</mixed-citation><mixed-citation xml:lang="en">Shalnova SA, Vilkov VG, Metelskaya VA, et al. Thirty-Year Changes in Average Blood Lipids Levels in Populations of the Russian Federation and the USA. Rational Pharmacotherapy in Cardiology. 2018;14(1):4-11. (In Russ). doi:10.20996/1819-6446-2018-14-1-4-11.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020;14(5):1463-5. doi:10.1016/j.dsx.2020.07.054.</mixed-citation><mixed-citation xml:lang="en">Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020;14(5):1463-5. doi:10.1016/j.dsx.2020.07.054.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cao X, Yin R, Albrecht H, et al. Cholesterol: A new game player accelerating vasculopathy caused by SARS-CoV-2? Am J Physiol Endocrinol Metab. 2020;319(1):197-202. doi:10.1152/ajpendo.00255.2020.</mixed-citation><mixed-citation xml:lang="en">Cao X, Yin R, Albrecht H, et al. Cholesterol: A new game player accelerating vasculopathy caused by SARS-CoV-2? Am J Physiol Endocrinol Metab. 2020;319(1):197-202. doi:10.1152/ajpendo.00255.2020.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.</mixed-citation><mixed-citation xml:lang="en">Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDLcholesterol and apolipoprotein B compared with LDLcholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148-54. doi:10.1016/j.pathol.2018.11.006.</mixed-citation><mixed-citation xml:lang="en">Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDLcholesterol and apolipoprotein B compared with LDLcholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148-54. doi:10.1016/j.pathol.2018.11.006.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Puri R, Nissen SE, Shao M, et al. Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events. Arterioscler Thromb Vasc Biol. 2016;36(11):2220-8. doi:10.1161/ATVBAHA.116.307601.</mixed-citation><mixed-citation xml:lang="en">Puri R, Nissen SE, Shao M, et al. Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events. Arterioscler Thromb Vasc Biol. 2016;36(11):2220-8. doi:10.1161/ATVBAHA.116.307601.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gazzola K, Reeskamp L, van den Born BJ. Ethnicity, lipids and cardiovascular disease. Curr Opin Lipidol. 2017;28(3):225-30. doi:10.1097/MOL.0000000000000412.</mixed-citation><mixed-citation xml:lang="en">Gazzola K, Reeskamp L, van den Born BJ. Ethnicity, lipids and cardiovascular disease. Curr Opin Lipidol. 2017;28(3):225-30. doi:10.1097/MOL.0000000000000412.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gazzola K, Snijder MB, Hovingh GK, et al. Ethnic differences in plasma lipid levels in a large multiethnic cohort: The HELIUS study. J ClinLipidol. 2018;12(5):1217-24.e1. doi:10.1016/j.jacl.2018.06.015.</mixed-citation><mixed-citation xml:lang="en">Gazzola K, Snijder MB, Hovingh GK, et al. Ethnic differences in plasma lipid levels in a large multiethnic cohort: The HELIUS study. J ClinLipidol. 2018;12(5):1217-24.e1. doi:10.1016/j.jacl.2018.06.015.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
